COVID-19 Global Updates & Resources

Sponsored by Oscotec Inc., this is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel dose study to evaluate the efficacy and safety of SKI-0-703, and SYK inhibitor, in patient’s with persistent and chronic ITP who have failed to respond (or relapsed after trying) other treatments. Patients in this study must have a platelet count less than 30,000μL on two separate occasion as at least 7 days apart. Participants will take part in three treatment groups for twenty weeks.

USA, Greece, Poland, Spain, Republic of Korea.